Working… Menu

Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02742090
Recruitment Status : Completed
First Posted : April 18, 2016
Last Update Posted : October 15, 2021
Information provided by (Responsible Party):
TG Therapeutics, Inc.